Glow Lifetech Corp (GLWLF) Fair Value & Analysis

Healthcare · US · Market cap $6.1M

Below-average quality, and screening another 32% overvalued on our models.

What matters now

• The price sits above even our optimistic bull case ($0.0250). The favourable scenario is already priced in.
• Weak quality (30/100) and above fair value at the same time, the margin of safety is missing on both counts.
• The large gap to fair value rests on thin data (low evidence): fewer applicable models and a shorter history. Read it with extra caution.

Price vs Fair Value (5 years)

White line = price, green steps = our fair value per fiscal year, dashed = 300-day average. As of Jul 29, 2026.

How to read this chart

57‑month range $0.0203 – $0.3545 · the $0.0368 price screens above the $0.0250 fair value. Dashed = 300-day average. As of Jul 29, 2026.

Full chart & analysis →

Which stocks are undervalued right now? Check free Discover now →

Analysis

Glow Lifetech Corp (GLWLF) currently trades at $0.0368, while our model-based Fair Value estimate is $0.0250, implying the stock looks roughly 32.1% overvalued today. The Quality Score stands at 30/100 (below-average quality), in the Healthcare sector. Bear case: priced above our estimate, the market already discounts strong expectations. Bull case: above-average quality can justify a premium, the entry price still matters most (evidence: low).

Over the trailing twelve months, Glow Lifetech Corp generated revenue of $2.2M at a net margin of -23.9%. Revenue grew 34.5% year over year. It earns a return on equity of -18.7%. Fundamentals as of Jul 29, 2026

The share trades about 22% below its 52-week high and 15% above its 52-week low, currently below its 200-day average. For context, the median of 10 Healthcare peers we cover trades at -43% fair-value upside, at -32%, GLWLF screens cheaper than that median.

Fair Value models

Each model estimates fair value its own way; the Fair Value above is the evidence-weighted blend. Evidence (0–100) measures how completely this model’s inputs are available: well-fed models carry more weight in the blend. The spread across models is intentional, each one stresses a different value driver; dividend models, for instance, come out structurally low when payout is small.

Key figures & financial health

Quality Score breakdown

About the company

Glow Lifetech Corp., an ingredient technology company, focuses on producing nutraceutical and cannabinoid-based products. It engages in the commercialization of plant-based MyCell technology delivery system; water-soluble ingredients; customized blends; powder-based capsules, and market-ready products, as well as precision-dosed capsules.

Full company description

Glow Lifetech Corp., an ingredient technology company, focuses on producing nutraceutical and cannabinoid-based products. It engages in the commercialization of plant-based MyCell technology delivery system; water-soluble ingredients; customized blends; powder-based capsules, and market-ready products, as well as precision-dosed capsules. The company has exclusive North American rights for the production, sale, and distribution rights for the certain micellization technology for cannabis and hemp derived ingredients, curcumin, vitamin K and iron. It also engages in the business of secondary processing of ingredients to produce micellized materials from certain vitamins, nutraceuticals, and cannabis extracts that makes fat-soluble substances available for immediate absorption into the body reach near 100% bioavailability and water compatibility. The company provides its products under MOD and .decimal brand names. Glow Lifetech Corp. was founded in 1988 and is headquartered in Etobicoke, Canada.

Company description, as reported by the company or data provider.

Revenue & earnings trend

FY2021 – FY2025 · reported fiscal years

Glow Lifetech Corp reported revenue of $2.1M in FY2025 versus $0 in FY2021. Reported net income was −$618K in FY2025.

GLWLF screens 32% overvalued. Compare with Vertex Pharmaceuticals Incorporated →

Peer Group

Biotechnology · 601 stocks

How this stock ranks against its industry: the green marker is this stock, the band is the typical 25–75% peer range, and the tick is the median.

Valuation Multiples vs Biotechnology median · lower = cheaper

Snowflake

Five quick dimensions, each 0 to 100: VALUE (fair-value potential), FUTURE (revenue growth), PAST (return on equity), HEALTH (low debt), DIVIDEND (yield). Green = this stock, grey = typical sector peer.

VALUE 0: the price sits above our fair-value range.

Values & ESG

Does this company touch areas you may want to avoid? The classification is inferred from sector and industry.

ESG scores are not available for this stock yet. Values and ESG data are contextual and can differ between providers.

Similar stocks

10 more Biotechnology stocks, each showing price versus our Fair Value estimate (as of Jul 29, 2026).

Explore undervalued stocks

More undervalued Healthcare stocks →

Frequently asked questions

How we calculate Fair Value

Each company is valued through a stack of independent intrinsic-value models (DCF variants, residual-income, multiples and more), blended into one family-balanced consensus and weighted by how much trustworthy data backs it. A separate quality layer scores the fundamentals. Every input is real reported data, nothing guessed.